Revista Médica del Hospital General de México (Jan 2018)

Expression of cancer testis antigens in patients with Hodgkin's lymphoma and their clinical correlation

  • L.M. Hodgson Reyes,
  • I. Olarte Carrillo,
  • C.O. Ramos Peñafiel,
  • A. Martínez Tovar,
  • E. Gallardo,
  • H. Castellanos Sinco,
  • J. Collazo Jaloma

DOI
https://doi.org/10.1016/j.hgmx.2016.11.005
Journal volume & issue
Vol. 81, no. 1
pp. 27 – 34

Abstract

Read online

Objective: To determine the frequency of expression of cancer testis antigens and their clinical correlation in patients with Hodgkin lymphoma. Methodology of the study: In this analytical, experimental and ambispective study, the MAGE A-3 and NY-ESO-1 antigen expression was correlated with clinical prognostic variables such as clinical stage, response to treatment, and relapse, in a total of 70 patients diagnosed with Hodgkin's lymphoma at the Hodgkin's Lymphoma Clinic of the General Hospital of Mexico “Dr. Eduardo Liceaga”, from December 2000 to December 2015. Twenty-four patients were evaluated using RT-PCR, following extraction of RNA, to detect MAGE-A3 and NY-ESO1 expression. Cellular RNA was extracted from frozen tissue and controls using trizol (Life Technologies, Paisley, UK). 1 μg of RNA was used for cDNA synthesis by M-MLV reverse transcriptase (Life technologies, Paisley, UK). Results: We studied 24 patients with a median age of 28 years, a minimum age of 16 years and a maximum age of 48 years, mostly male. 50% of patients presented complete response to the first line of treatment and 27% of patients presented relapse, 37.5% in relation to the expression of MAGE-A3. Expression of the NY-ESO-1 gene was not found in the study group. Twelve percent of patients died during the study, 8.33% of whom were also positive for MAGE-A3 (p = 0.264.95% CI). No significant correlation was found between MAGE-A3 expression and major clinical prognostic variables. Conclusion: Although the expression of MAGE-A3 in the study group was 37.5% (higher than reported in international studies), we found no correlation with the main clinical prognostics variables. Considering that the expression of MAGE-A3 in the cases studied does not confer prognostic value, making it impossible to use as a prognostic tool in peripheral blood, we are leaving the doors open to continue with this line of research, possibly increasing the number of patients as well as prolonging the follow-up time.

Keywords